Lexicon Pharmaceuticals (LXRX) Total Debt (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Total Debt data on file, last reported at $49.7 million in Q1 2026.

• Total Debt for Q1 2026 came in at $49.7 million, down 50.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.7 million (down 50.66% YoY), and the FY2025 annual result was $54.0 million, down 46.16% from the prior year.
• Total Debt declined to $49.7 million in Q1 2026 per LXRX's latest filing, from $54.0 million in the prior quarter.
• Over five years, Total Debt peaked at $100.7 million in Q1 2025 and troughed at $23.5 million in Q1 2022.
• A 5-year average of $69.6 million and a median of $56.5 million in 2025 frame the typical range for Total Debt.
• The sharpest annual moves came in 2023 and 2026: Total Debt jumped 317.98% in 2023, then sank 50.66% in 2026.
• A 5-year view of Total Debt shows it stood at $48.6 million in 2022, then jumped by 104.84% to $99.5 million in 2023, then increased by 0.79% to $100.3 million in 2024, then slumped by 46.16% to $54.0 million in 2025, then fell by 8.0% to $49.7 million in 2026.
• Business Quant data shows LXRX's Total Debt at $49.7 million in Q1 2026, $54.0 million in Q4 2025, and $56.5 million in Q3 2025.